Literature DB >> 30205165

Identification of a High-Level MET Amplification in CTCs and cfTNA of an ALK-Positive NSCLC Patient Developing Evasive Resistance to Crizotinib.

Lars-Arne Berger1, Melanie Janning2, Janna-Lisa Velthaus2, Isabel Ben-Batalla2, Stefanie Schatz3, Markus Falk3, Peter Iglauer4, Ronald Simon4, Ru Cao5, Claudio Forcato6, Nicolò Manaresi6, Kelli Bramlett5, Genny Buson6, Annkathrin Hanssen7, Markus Tiemann3, Guido Sauter4, Carsten Bokemeyer1, Sabine Riethdorf7, Martin Reck8, Klaus Pantel7, Harriet Wikman7, Sonja Loges9.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30205165     DOI： 10.1016/j.jtho.2018.08.2025

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  9 in total

Review 1.  Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells.

Authors:  Laura Keller; Klaus Pantel
Journal:  Nat Rev Cancer       Date:  2019-08-27       Impact factor: 60.716

Review 2.  Targeting the HGF/MET Axis in Cancer Therapy: Challenges in Resistance and Opportunities for Improvement.

Authors:  Xing Huang; Enliang Li; Hang Shen; Xun Wang; Tianyu Tang; Xiaozhen Zhang; Jian Xu; Zengwei Tang; Chengxiang Guo; Xueli Bai; Tingbo Liang
Journal:  Front Cell Dev Biol       Date:  2020-05-06

Review 3.  DEPArray™ system: An automatic image-based sorter for isolation of pure circulating tumor cells.

Authors:  Mariano Di Trapani; Nicolò Manaresi; Gianni Medoro
Journal:  Cytometry A       Date:  2018-12       Impact factor: 4.355

Review 4.  Resistance to anaplastic lymphoma kinase inhibitors: knowing the enemy is half the battle won.

Authors:  Fabrizio Tabbò; Maria Lucia Reale; Paolo Bironzo; Giorgio V Scagliotti
Journal:  Transl Lung Cancer Res       Date:  2020-12

5.  EGFR/MET promotes hepatocellular carcinoma metastasis by stabilizing tumor cells and resisting to RTKs inhibitors in circulating tumor microemboli.

Authors:  Shouyang Song; Zhen Yu; Yajing You; Chenxi Liu; Xiaoyu Xie; Huanran Lv; Feng Xiao; Qiang Zhu; Chengyong Qin
Journal:  Cell Death Dis       Date:  2022-04-15       Impact factor: 9.685

6.  The Opportunities and Challenges of Molecular Tagging Next-Generation Sequencing in Liquid Biopsy.

Authors:  Giuseppa De Luca; Mariella Dono
Journal:  Mol Diagn Ther       Date:  2021-07-05       Impact factor: 4.074

Review 7.  Frontiers of ctDNA, targeted therapies, and immunotherapy in non-small-cell lung cancer.

Authors:  Chennianci Zhu; Weihao Zhuang; Limin Chen; Wenyu Yang; Wen-Bin Ou
Journal:  Transl Lung Cancer Res       Date:  2020-02

8.  Discovery of Targetable Genetic Alterations in NSCLC Patients with Different Metastatic Patterns Using a MassARRAY-Based Circulating Tumor DNA Assay.

Authors:  Yassine Belloum; Melanie Janning; Malte Mohme; Ronald Simon; Jolanthe Kropidlowski; Alexander Sartori; Darryl Irwin; Manfred Westphal; Katrin Lamszus; Sonja Loges; Sabine Riethdorf; Klaus Pantel; Harriet Wikman
Journal:  Cells       Date:  2020-10-22       Impact factor: 6.600

9.  NGS-based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment.

Authors:  Estela Sánchez-Herrero; Roberto Serna-Blasco; Vadym Ivanchuk; Rosario García-Campelo; Manuel Dómine Gómez; José M Sánchez; Bartomeu Massutí; Noemi Reguart; Carlos Camps; Sandra Sanz-Moreno; Silvia Calabuig-Fariñas; Eloísa Jantus-Lewintre; Magdalena Arnal; Dietmar Fernández-Orth; Virginia Calvo; Víctor González-Rumayor; Mariano Provencio; Atocha Romero
Journal:  Mol Oncol       Date:  2021-06-18       Impact factor: 6.603
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.